Ординатура / Офтальмология / Английские материалы / Electrophysiology of Vision_Lam_2005

26.Stelmach MZ, O’Day J. Partly reversible visual failure with methanol toxicity. Aust NZ J Ophthalmol 1992; 20:57–64.

27.McKellar MJ, Hidajat RR, Elder MJ. Acute ocular methanol toxicity. Aust NZ J Ophthalmol 1997; 25:225–230.

28.Ruedemann AD. The electroretinogram in chronic methyl alcohol poisoning in human beings. Am J Ophthalmol 1962; 54:34–53.

29.Ingemansson SO. Clinical observations on ten cases of methanol poisoning with particular reference to ocular manifestations. Acta Ophthalmol 1984; 62:15–24.

30.Murray TG, Burton TC, Rajani C, Lewandowski MF, Burke JM, Eells JT. Methanol poisoning: a rodent model with structural and functional evidence for retinal involvement. Arch Ophthalmol 1991; 109:1012–1016.

31.Fishman GA, Birch DG, Holder GE, Brigell MG. Methanol. Electrophysiologic Testing in Disorders of the Retina, Optic Nerve, and Visual Pathway. San Francisco: The Foundation of the American Academy of Ophthalmology, 2001:95–96.

32.Karpe G. The basis of clinical electroretinography. Acta Ophthalmol 1945: 24 (suppl):1–118.

33.Potts AM, Proglin J, Farkas I, Orbison L, Chickering D. Studies on the visual toxicity of methanol. Am J Ophthalmol 1955; 40:76–83.

34.Brown RD, Grattan CEH. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989; 73:286–288.

35.Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986; 104:831–837.

36.Bernstein HN. Chloroquine ocular toxicity. Surv Ophthalmol 1967; 12:415–447.

37.Finbloom DS, Silver K, Newsome DA, Gunkel RD. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985; 12:692–694.

38.Morsman CD, Liversey SJ, Richards JM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990; 4:572–576.

39.Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983; 75:35–39.

40.Mavrikakis I, Sfikakis PP, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003; 110:1321–1326.

41.Krill AE, Potts AM, Johanson CE. Chloroquine retinopathy: investigation of discrepancy between dark adaptation and electroretinographic findings in advanced stages. Am J Ophthalmol 1971; 71:530–534.

42.Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55:187–189.

43.Penrose PJ, Tzekov RT, Sutter EE, Fu AD, Allen AW, Fung WE, Oxford KW. Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 2003; 23:503–512.

44.So SC, Hedges TR, Schuman JS, Quireza ML. Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. Ophthalmic Surg Lasers Imaging 2003; 34:251–258.

45.Moschos MN, Moschos MM, Apostolopoulos M, Mallias JA, Bouros C, Theodossiadis GP. Assessing hydroxychloroquine toxicity by the multifocal ERG. Doc Ophthalmol 2004; 108:47–53.

46.Tzekov RT, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc Ophthalmol 2004; 108:87–97.

47.Pinckers A, Broekhuyse RM. The EOG in rheumatoid arthritis. Acta Ophthalmol 1983; 61:831–837.

48.Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol 1991; 112:528–534.

49.Sassaman FW, Cassidy JT, Alpern M. Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine. Am J Ophthalmol 1970; 77:515–523.

50.Percival SP. The ocular toxicity of chloroquine. Trans Ophthalmol Soc UK 1967; 87:355–357.

51.Marmor MF. Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol 1990; 74:739–742.

52.Meredith TA, Aaberg TM, Willerson WD. Progressive chorioretinopathy after receiving thioridazine. Arch Ophthalmol 1978; 96:1172–1176.

53.Davidorf FH. Thioridazine pigmentary retinopathy. Arch Ophthalmol 1973; 90:251–255.

54.Appelbaum A. An ophthalmoscopic study of patients under treatment with thioridazine. Arch Ophthalmol 1963; 69:578–580.

55.Siddall JR. Ocular toxic changes associated with chlorpromazine and thioridazine. Can J Ophthalmol 1966; 1:190–198.

56.Filip V, Balik J. Possible indication of dopaminergic blockade in man by electroretinography. Int Pharmacopsychiatry 1978; 13:151–156.

57.Miyata M, Imai H, Ishikawa S, Nakajima S. Change in human electroretinography associated with thioridazine administration. Ophthalmologica 1980; 181:175–180.

58.Godel V, Loewenstein A, Lazar M. Spectral electroretinography in thioridazine toxicity. Ann Ophthalmol 1990; 22: 293–296.

59.Saletu B, Saletu M, Simeon J, Viamontes G, Itil TM. Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children. Biol Psychiatry 1975; 10:253–275.

60.Boet D. Toxic effects of phenothiazines on the eye. Doc Ophthalmol 1970; 28:16–69.

61.Henkes HE. Electro-oculography as a diagnostic aid in phenothiazin retinopathy. Trans Ophthalmol Soc UK 1967; 87:285–287.

62.Alkemade PP. Phenothiazine-retinopathy. Ophthalmologica 1968; 155:70–76.

63.Cibis BW, Burian HM, Blodi FC. Electroretinogram changes in acute quinine poisoning. Arch Ophthalmol 1973; 90: 307–309.

64.Brinton GS, Norton EWD, Zahn JR, Knighton RW. Ocular quinine toxicity. Am J Ophthalmol 1980; 90:403–410.

65.Yospaiboon Y, Lawtiantong T, Chotibutr S. Clinical observations of ocular quinine intoxication. Jpn J Ophthalmol 1984; 28:409–415.

66.Canning CR, Hague S. Ocular quinine toxicity. Br J Ophthalmol 1988; 72:23–26.

67.Moloney JB, Hillery M, Fenton M. Two year electrophysiology follow-up in quinine amblyopia: a case report. Arch Ophthalmol 1987; 65:731–734.

68.Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988; 72:219–214.

69.Franc¸ois J, de Rouck A, Cambie E. Retinal and optic evaluation in quinine poisoning. Ann Ophthalmol 1972; 4:177–185.

70.Behrman J, Mushin A. Electrodiagnostic findings in quinine amblyopia. Br J Ophthalmol 1968; 52:925–928.

71.Cohen A, Martin M, Mizanin J, Kankle DF, Schwartz E. Vision and hearing during deferoxamine therapy. J Pediatr 1990; 117:326–330.

72.De Virgiliis S, Congia M, Turco MP, Trau F, Dessi C, Argiolu F, Sorcinelli R, Sitzia A, Cao A. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child 1988; 63:250–255.

73.Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002; 109:164–171.

74.Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986; 70:373–381.

75.Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single ‘‘challange’’ dose of deferoxamine. Clin Nephrol 1987; 31:45–48.

76.Ravelli M, Scaroni P, Mombelloni S, Movilli E, Feller P, Apostoli P, De Maria G, Valotti C, Sciuto G, Maiorca R. Acute visual disorders in patients on regular dialysis given

desferrioxamine as a test. Nephrol Dial Transplant 1990; 5:945–949.

77.Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2:181–184.

78.Lakhampal V, Schocket SS, Jiji R. Deferoxamine (desferal)- induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984; 91:443–451.

79.Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985; 20:153–156.

80.Triantafyllou N, Fisfis M, Sideris G, Triantafyllou D, Rombos A, Vrettou H, Mantouvalos V, Politi C, Malliara S, Papageorgiou C. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment. Acta Neurol Scand 1991; 83:306–308.

81.Taylor MJ, Keenan NK, Gallant T, Skarf B, Freedman MH, Logan WJ. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy. Longitudinal studies. Electroencephalogr Clin Neurophysiol 1987; 68:81–87.

82.Gelmi C, Borgna-Pignatti C, Franchin S, Tacchini M, Trimarchi F. Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major. Ophthalmologica 1988; 196:29–34.

83.Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792–1798.

84.Ka¨fvia¨inen R, Nousiainen I, Ma¨ntyja¨vi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53:922–926.

85.Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50:614–618.

86.Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67:716–722.

87.Coupland SG, Zackon DH, Leonard BC, Ross TM. Vigabatrin effect on inner retinal function. Ophthalmology 2001; 108:1493–1496.

88.Dong C-J, Hare WA. GABAc feedback pathway modulates the amplitude and kinetics of ERG b-wave in a mammalian retina in vivo. Vision Res 2002; 42:1081–1087.

89.Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53:2082–2087.

90.Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. Br Med J 1997; 314:180–181.

91.Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55:40–45.

92.Weatall CA, Nobile R, Morong S, Buncic JR, Logan WJ, Panton CM. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 2003; 107:299–309.

93.Jensen H, Sjo¨ O, Udall P, Gram L. Vigabatrin and retinal changes. Doc Ophthalmol 2002; 104:171–180.

94.van der Torren K, Graniewski-Wijnands HS, Polak BCP. Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 2002; 104:181–188.

95.Harding GF, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 2000; 55:347–352.

96.Ponjavic V, Andreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 2001; 102:63–72.

97.Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M. The hospital for sick children, Toronto, longitudi-

nal ERG study of children on vigabatrin. Doc Ophthalmol 2002; 104:133–149.

98.Besch D, Kurtenbach A, Apfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schieter U. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 2002; 104:151–170.

99.Morong S, Weatall CA, Nobile R, Buncic JR, Logan WJ, Panton CM, Abdolell M. Longitudinal changes in photopic OPs occurring with vigabatrin treatment. Doc Ophthalmol 2003; 107:289–297.

100.Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 1998; 116:817–819.

101.Harding GF, Wild JM, Robertson KA, Lawden MC, Betts TA, Barber C, Barnes PM. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia 2000; 41:1420–1431.

102.Banin E, Shalev RS, Obolnesky A, Neis R, Chowers I, GrossTsur V. Retinal function abnormalities in patients treated with vigabatrin. Arch Ophthalmol 2003; 121:811–816.

103.Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52:1201–1205.

104.Hardus P, Verduin WM, Berendschot TT, Kamermans M, Postma G, Stilma JS, van Veelen CW. The value of electrophysiology results in patients with epilepsy and vigabatrin associated visual field loss. Acta Ophthalmol Scand 2001; 79:169–174.

105.Harding GFA, Robertson K, Spencer EL, Holliday I. Vigabatrin: its effect on the electrophysiology of vision. Doc Ophthalmol 2002; 104:213–229.

106.Spencer EL, Harding GFA. Examining visual field defects in the paediatric population exposed to vigabatrin. Doc Ophthalmol 2003; 107:289–297.

107.Comaish IF, Gorman C, Brinlow GM, Barber C, Orr GM, Galloway NR. The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 2002; 104:195–212.

108.Graniewski-Wijnands HS, van der Torren K. Electroophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 2002; 104:189–194.

109.Marmor MF, Kessler R. Sildenafil (viagra) and ophthalmology. Surv Ophthalmol 1999; 44:153–162.

110.McCulley TJ, Lam BL, Marmor MF, Hoffman KB, Luu JK, Feuer WJ. Acute effects of sildenafil on blue-on-yellow and white-on-white Humphrey perimetry. J Neuro-Ophthalmol 2000; 20:227–228.

111.Vobig MA, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P. Retinal side-effects of sildenafil. Lancet 1999; 353:375.

112.Gabrieli CB, Regine F, Vingolo EM, Rispoli E, Fabbri A, Isodori A. Subjective visual halos after sildenafil (viagra) administration: electroretinographic evaluation. Ophthalmology 2001; 108:877–881.

113.Gabrieli CB, Regine F, Vingolo EM, Rispoli E, Isidori A. Acute electroretinographic changes during sildenafil (viagra) treatment for erectile dysfunction. Doc Ophthalmol 2003; 107:111–114.

114.Luu JK, Chappelow AV, McCulley TJ, Marmor MF. Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol 2001; 132:388–394.

115.Jagle H, Jagle C, Serey L, Yu A, Rilk A, Sadowski B, Besch D, Zrenner E, Sharpe LT. Visual short-term effects of viagra: double blind study in healthy young subjects. Am J Ophthalmol 2004; 137:842–849.

116.Behn D, Potter MJ. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. Invest Ophthalmol Vision Sci 2001; 42:523–527.

117.D’Amico DJ, Caspers-Velu L, Libert J, Shanks E, Schrooyen M, Hanninen LA, Kenyon KR. Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol 1985; 100:264–275.

118.D’Amico DJ, Libert J, Kenyon KR, Hanninen LA, CaspersVelu L. Retinal toxicity of intravitreal gentamicin. An electron microscopic study.. Invest Ophthalmol Vision Sci 1984; 25:564–572.

119.Kawasaki K, Ohnogi J. Nontoxic concentration of kanamycin and gentamicin for intravitreal use—evaluated by in vitro ERG. Doc Ophthalmol 1988; 70:301–308.

120.Kawasaki K, Mochizuki K, Torisaki M, Yamashita Y, Shirao Y, Wakabayashi K, Tanabe J. Electroretinographical changes due to antimicrobials. Lens Eye Toxic Res 1990; 7:693–704.

121.Palimeris G, Moschos M, Chimonidou E, Panagakis E, Andreanos D, Smirnof T. Retinal toxicity of antibiotics: evaluation by electroretinogram. Doc Ophthal Proc Ser 1978; 15:45–52.

122.Loewenstein A, Zemel E, Vered Y, Lazar M, Perlman I. Retinal toxicity of gentamicin after subconjunctival injection performed adjacent to thinned sclera. Ophthalmology 2001; 108:759–764.

123.Brown GC, Eagle RC, Shakin EP, Gruber M, Arbizio VV. Retinal toxicity of intravitreal gentamicin. Arch Ophthalmol 1990; 108:1740–1744.

124.Yiannikas C, Walsh JC, McLeod JG. Visual evoked potentials in the detection of subclinical optic toxic effects secondary to ethambutol. Arch Neurol 1983; 40:645–648.

125.Kakisu Y, Adachi-Usami E, Mizota A. Pattern electroretinogram and visual evoked cortical potential in ethambutol optic neuropathy. Doc Ophthalmol 1987; 67:327–334.

126.Nasemann J, Zrenner E, Riedel KG. Recovery after severe ethambutol intoxication—psychophysical and electrophysiological correlations. Doc Ophthalmol 1989; 71:279–292.

127.Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Ocul Pharmacol Ther 1995; 11:411–419.

128.Woung LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmacol Ther 1995; 11:411–419.

129.Yen MY, Wang AG, Chiang SC, Liu JH. Ethambutol retinal toxicity: an electrophysiologic study. J Formos Med Assoc 2000; 99:630–634.

130.Wilding G, Caruso RC, Lawrence TS, Ostchega Y, Ballintine EJ, Young RC, Ozols RF. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985; 3:1683–1689.

131.Hilliard LM, Berkow RL, Watterson J, Ballard EA, Balzer GK, Moertel CL. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997; 28:310–313.

132.Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 1993; 84:237–246.

133.Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N. Persistent severe visual and electroretinographic abnormalities after intravenous cisplatin therapy. J Neuro-Ophthalmol 2003; 23:132–135.

134.Maiese K, Walker RW, Gargan R, Victor JD. Intra-arterial cisplatin-associated optic and otic toxicity. Arch Neurol 1992; 49:83–86.

135.Henkes HE, van Lith GH, Canta LR. Indomethacin retinopathy. Am J Ophthalmol 1972; 73:846–856.

136.Burns CA. Indomethacin, reduced retinal sensitivity, and corneal deposits. Am J Ophthalmol 1968; 66:825–835.